Impaired production of IL-12 in systemic lupus erythematosus.: III:: Deficient IL-12 p40 gene expression and cross-regulation of IL-12, IL-10 and IFN-γ gene expression

被引:23
作者
Liu, TF
Jones, BM
Wong, RWS
Srivastava, G
机构
[1] Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China
关键词
cytokines; gene expression; IL-12; lupus;
D O I
10.1006/cyto.1999.0512
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interleukin 12 (IL-12) is a heterodimer comprising p35 and p40 subunits which are encoded and regulated separately, The authors previously demonstrated deficient IL-12 production in SLE which correlates negatively with disease activity. The present study was designed to determine whether deficiency of IL-12 and excess production of IL-10 and IL-6 in systemic lupus erythematosus (SLE) are due to aberrant regulation at the gene level, Using semiquantitative RT-PGR assay, it was shown that constitutive expression of IL-12 p35 gene is somewhat impaired in SLE compared with controls and that IL-12 p40 mRNA, which was present at low levels in controls, was undetectable in unstimulated SLE peripheral blood mononuclear cells (PBMG). Gene expression of IL-12 p35 and p40 was significantly increased in response to SAG, with significantly lower SAG-induced expression of p40 in SLE patients than controls. SAG-stimulated IL-12 p35 and p40 mRNAs were significantly augmented by interferon gamma IFN-gamma. Exogenous IL-12 or IFN-gamma significantly inhibited IL-10 gene expression, without affecting IL-6 mRNA or other proinflammatory cytokine mRNA levels. These observations were further confirmed by studies of protein production at the single cell level using ELISPOT assay. Downregulation of IL-12 p40 expression appears to be the cause of IL12 p70 deficiency in SLE. If this defect could be repaired, normalization of IL-12 and IFN-gamma production should reduce excessive IL-10 and prevent pathology. (C) 1999 Academic Press.
引用
收藏
页码:805 / 811
页数:7
相关论文
共 36 条
[1]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[2]   INTERLEUKIN-10 (IL-10) INHIBITS HUMAN LYMPHOCYTE INTERFERON GAMMA-PRODUCTION BY SUPPRESSING NATURAL-KILLER-CELL STIMULATORY FACTOR/IL-12 SYNTHESIS IN ACCESSORY CELLS [J].
DANDREA, A ;
ASTEAMEZAGA, M ;
VALIANTE, NM ;
MA, XJ ;
KUBIN, M ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :1041-1048
[3]   PRODUCTION OF NATURAL-KILLER-CELL STIMULATORY FACTOR (INTERLEUKIN-12) BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS [J].
DANDREA, A ;
RENGARAJU, M ;
VALIANTE, NM ;
CHEHIMI, J ;
KUBIN, M ;
ASTE, M ;
CHAN, SH ;
KOBAYASHI, M ;
YOUNG, D ;
NICKBARG, E ;
CHIZZONITE, R ;
WOLF, SF ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1387-1398
[4]  
DE WMR, 1991, J EXP MED, V174, P1209
[5]   LOCAL SUPPRESSION OF EPSTEIN-BARR-VIRUS (EBV)-SPECIFIC CYTOTOXICITY IN BIOPSIES OF EBV-POSITIVE HODGKINS-DISEASE [J].
FRISAN, T ;
SJOBERG, J ;
DOLCETTI, R ;
BOIOCCHI, M ;
DE RE, V ;
CARBONE, A ;
BRAUTBAR, C ;
BATTAT, S ;
BIBERFELD, P ;
ECKMAN, M ;
OST, O ;
CHRISTENSSON, B ;
SUNDSTROM, C ;
BJORKHOLM, M ;
PISA, P ;
MASUCCI, MG .
BLOOD, 1995, 86 (04) :1493-1501
[6]   COEXPRESSION OF 2 DISTINCT GENES IS REQUIRED TO GENERATE SECRETED BIOACTIVE CYTOTOXIC LYMPHOCYTE MATURATION FACTOR [J].
GUBLER, U ;
CHUA, AO ;
SCHOENHAUT, DS ;
DWYER, CM ;
MCCOMAS, W ;
MOTYKA, R ;
NABAVI, N ;
WOLITZKY, AG ;
QUINN, PM ;
FAMILLETTI, PC ;
GATELY, MK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (10) :4143-4147
[7]  
Harrison TS, 1996, J IMMUNOL, V156, P4492
[8]  
Harrison TS, 1997, J IMMUNOL, V158, P459
[9]   CYTOKINE GENE PROFILE IN CIRCULATING BLOOD MONONUCLEAR-CELLS FROM PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS - INCREASED INTERLEUKIN-2 BUT NOT INTERLEUKIN-4 MESSENGER-RNA [J].
HORWITZ, DA ;
WANG, H ;
GRAY, JD .
LUPUS, 1994, 3 (05) :423-428
[10]  
Horwitz DA, 1998, ARTHRITIS RHEUM, V41, P838, DOI 10.1002/1529-0131(199805)41:5<838::AID-ART10>3.0.CO